U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H13N3O
Molecular Weight 203.2408
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUMANIROLE

SMILES

CN[C@]1([H])Cc2cccc3c2n(C1)c(n3)O

InChI

InChIKey=RKZSNTNMEFVBDT-MRVPVSSYSA-N
InChI=1S/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)/t8-/m1/s1

HIDE SMILES / InChI

Molecular Formula C11H13N3O
Molecular Weight 203.2408
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Sumanirole is a novel dopamine agonist with high affinity and efficacy at D2 dopamine receptors and has a substantial degree of selectivity for the D2 receptor over other dopamine receptor subtypes. It had been in clinical trials for the treatment of Parkinson’s disease and restless leg syndrome but these studies were terminated for the efficacy reason.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
1 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Disc. AE: dizziness, Headaches...
AEs leading to
discontinuation/dose reduction:
dizziness (1 pt)
Headaches (1 pt)
Sources:
2 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 59
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 59
Sources:
Disc. AE: Nausea and vomiting, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea and vomiting (1 pt)
Dizziness (1 pt)
insomnia (1 pt)
dizziness (1 pt)
diarrhea (1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headaches 1 pt
Disc. AE
1 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
dizziness 1 pt
Disc. AE
1 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Dizziness 1 pt
Disc. AE
2 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 59
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 59
Sources:
Nausea and vomiting 1 pt
Disc. AE
2 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 59
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 59
Sources:
diarrhea 1 pt
Disc. AE
2 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 59
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 59
Sources:
dizziness 1 pt
Disc. AE
2 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 59
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 59
Sources:
insomnia 1 pt
Disc. AE
2 mg 1 times / day multiple, oral (unknown)
Studied dose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 59
Health Status: unhealthy
Condition: restless legs syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 59
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
U-95666E: a potential anti-parkinsonian drug with anxiolytic activity.
1997 Jul
Effects of selective activation of dopamine D2 and D3 receptors on prolactin secretion and the activity of tuberoinfundibular dopamine neurons.
1997 Sep 17
Dopamine receptor agonists differ in their actions on cardiac ion channels.
2003 Dec 15
Sumanirole Pharmacia.
2003 Jan
Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
2005 Sep
The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys.
2005 Sep
Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs.
2006 Mar
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists.
2007 Aug
Asymmetric synthesis of tetrahydroquinolin-3-ols via CoCl2-catalyzed reductive cyclization of nitro cyclic sulfites with NaBH4.
2009 Feb 19
Patents

Sample Use Guides

1 to 16 mg/day
Route of Administration: Oral
Sumanirole activated D2 receptor-stimulated mitogenesis with an EC50 of 4.6 nM, but it had no activity at D3 and D4 receptors in measurements of receptor-activated mitogenesis at concentrations up to 1 uM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:05:21 UTC 2021
Edited
by admin
on Sat Jun 26 04:05:21 UTC 2021
Record UNII
3E93IV1U45
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUMANIROLE
INN   WHO-DD  
INN  
Official Name English
(R)-5,6-DIHYDRO-5-(METHYLAMINO)-4H-IMIDAZO(4,5,1-IJ)QUINOLIN-2(1H)-ONE
Systematic Name English
SUMANIROLE [INN]
Common Name English
PNU-95666
Common Name English
SUMANIROLE [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
Code System Code Type Description
EVMPD
SUB25219
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
PRIMARY
PUBCHEM
9818479
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
PRIMARY
ChEMBL
CHEMBL419792
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
PRIMARY
FDA UNII
3E93IV1U45
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
PRIMARY
CAS
179386-43-7
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
PRIMARY
NCI_THESAURUS
C76651
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
PRIMARY
INN
8051
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
PRIMARY
DRUG BANK
DB06477
Created by admin on Sat Jun 26 04:05:21 UTC 2021 , Edited by admin on Sat Jun 26 04:05:21 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY